ILSI-Biomed Israel

Enzymotec: a $20 M Deal with Daiichi Sankyo

Israeli biotech company Enzymotec Ltd., a developer of active pharmaceutical ingredients for nutritional supplements, has signed a major strategic agreement with Daiichi Sankyo Brazil, a subsidiary of Japanese pharmaceutical company Daiichi Sankyo Co. Ltd. (TSE: 4568). Globes, 6 May Enzymotec and Daiichi Sankyo Brazil will launch Enzymotec's product for the reduction of cholesterol and triglycerides, which Daiichi Sankyo Brazil will market. Daiichi Sankyo Brazil focuses on cardiology a...

June 13th: From Idea to Bench to Bedside – a Biomedical Innovation Summit

Medical Innovation:  From Idea to Bench to Bedside A Biomedical Innovation Summit Dan Panorama Tel Aviv ¡ Sunday, June 13, 2010     Presented by Cleveland Clinic Global Cardiovascular Innovation Center Israel Life Sciences Industries   And Sponsored By GT Greenberg Traurih, MPR, PriceWaterhouseCoopers, Team Neo, Cleveland Plus Business         Program 8:45                 Registration, Breakfast, Networking 9:15                 Welcome and Introductions                ...

How to Handle Too Much Medical Information?

In a world choke-full of information, how can you get your medical information to the target audience? Lately, I’ve been noticing a curious behavior pattern on my side. It all began when my incoming e-mails quota went higher than twenty per day. I simply could not take the time to reply to them all, and some were left almost inevitably to the weekend, when it would take me half a day to collectively browse through and answer all of them. When talking to my colleagues I found out them some...

A 100 Million NIS Prosecution because of a Failed Anti-Hair-Loss Product

As reported in Calcalist, the company 'Taam Teva-Altman' is being sued for allegedly advertising a certain mixture of vitamins as a baldness-stopper, for a sum of 100 million NIS Nobody likes pseudoscience, least of all those of us in the drugs market, who have to compete against homeopathic medicines. Those remedies, while completely useless, are vastly superior to conventional medicines on one front: they do not have to be confirmed by the FDA and similar authorities. Pretty much any ch...

A New Competition by MATIMOP, ILSI and the Office of the Chief Scientist

A new competition by MATIMOP, ILSI and the Office of the Chief Scientist, may pave the way for Israeli companies to the Bio International Convention in Chicago Wherever there is competition, people strive for improvement. That's the basis of capitalism, and the reason why companies in the West are usually more efficient than their subsidized and nationalized counterparts in the east, or in the ancient Soviet Union. The free market constitutes a competition all by itself, but why not add s...

Medical Device Companies Embrace Social Media

An online survey reveals that medical device companies embrace social media slowly but surely. Everyone wants to advertise their wares to as many people as possible. However, it costs a lot to put your ad on TV or even on Ynet. The most simple solution, which more and more companies are beginning to use, is to create their own social media on the net: blogs, groups on Facebook, fan pages - they're all out there. And if they're written well enough, they can easily receive thousands of visi...

The 2009 Best Biomed Competition is Starting

The Life Science Accelerator (LSA)  is announcing the 2009 competition for Best Biomed Initiative, with a $ 47,450 worth first prize How would you like to give your start-up a major startup? The Life Science Accelerator (LSA) is giving Israelian biomed companies that kind of a chance, by opening the Best Biomed Initiative. The best company will win up to $ 47,450 worth (combined) of professional service package by the leading service providers, including full patent application draft serv...